Abbott Laboratories $ABT Shares Bought by State Street Corp

State Street Corp lifted its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 0.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 81,431,110 shares of the healthcare product maker’s stock after purchasing an additional 504,876 shares during the period. State Street Corp owned about 4.70% of Abbott Laboratories worth $8,047,837,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Farther Finance Advisors LLC lifted its stake in shares of Abbott Laboratories by 14.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock valued at $8,339,000 after acquiring an additional 10,431 shares during the last quarter. Juncture Wealth Strategies LLC purchased a new stake in Abbott Laboratories during the 3rd quarter valued at about $658,000. Thompson Investment Management Inc. boosted its holdings in Abbott Laboratories by 786.0% during the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock valued at $1,276,000 after acquiring an additional 12,474 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in Abbott Laboratories during the 2nd quarter valued at about $4,889,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Abbott Laboratories by 38.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,895,185 shares of the healthcare product maker’s stock worth $171,969,000 after acquiring an additional 522,279 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $102.96 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.00 and a debt-to-equity ratio of 0.57. The firm has a market cap of $178.32 billion, a P/E ratio of 38.42, a P/E/G ratio of 1.88 and a beta of 0.54. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $129.85. The firm has a 50-day moving average of $103.91 and a 200-day moving average of $101.66.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company had revenue of $13.01 billion for the quarter, compared to the consensus estimate of $12.99 billion. During the same quarter in the previous year, the business earned $1.30 EPS. Abbott Laboratories’s revenue was up 14.5% compared to the same quarter last year. Sell-side analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were issued a $0.63 dividend. The ex-dividend date was Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.

Key Headlines Impacting Abbott Laboratories

Investors following ABT have been watching these headlines:

  • Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, citing a more favorable outlook for the company. The higher rating is a potential bullish catalyst. Article
  • Positive Sentiment: Abbott initiated the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to improve valve deployment; successful development could strengthen Abbott’s cardiovascular device pipeline, though clinical and regulatory outcomes remain uncertain. Article
  • Neutral Sentiment: Articles noting that ABT is up 1.3% since its last earnings report revisit the results and look to earnings estimates for clues, but provide no specific new estimate revisions or fresh financial results. Article

Analysts Set New Price Targets

A number of equities analysts have commented on the company. BTIG Research decreased their price target on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. UBS Group dropped their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Royal Bank Of Canada cut their target price on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, October 22nd. Wells Fargo & Company raised their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. Finally, Leerink Partners raised shares of Abbott Laboratories from a “market perform” rating to an “outperform” rating and set a $124.00 target price on the stock in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $119.04.

Read Our Latest Stock Report on ABT

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Mary Moreland sold 3,500 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president owned 100,791 shares in the company, valued at $11,691,756. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Featured Articles

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.